---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/39995920.md"
description: "The Hong Kong stock market's biopharmaceutical sector showed significant divergence today 😔.WuXi Biologics fell by 3.9%, and CSPC Pharmaceutical Group fell by 4.2%. CROs and traditional pharmaceutical companies are under pressure from short-term valuation due to overseas compliance risk sentiment.CARsgen Therapeutics-B rose against the trend by 3.7%, reflecting selective capital attention on some innovative drug pipeline targets. Desheng-B remained largely flat.The overall valuation of Hong Kong-listed pharmaceutical stocks remains relatively low globally, but regulatory uncertainty and geopolitical sensitivity are persistent discount factors. It is necessary to distinguish between systemic sector pressure and individual stock alpha."
datetime: "2026-04-17T11:47:39.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39995920.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39995920.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39995920.md)
author: "[龙城旧梦](https://longbridge.com/en/profiles/26444980.md)"
---

# The Hong Kong stock market's biopharmaceutical sec…


### Related Stocks

- [02269.HK](https://longbridge.com/en/quote/02269.HK.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [02171.HK](https://longbridge.com/en/quote/02171.HK.md)
- [02526.HK](https://longbridge.com/en/quote/02526.HK.md)
- [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md)